OPEN-LABEL,MULTICENTRE, PHASE IB/II STUDY OF MEN1611, A PI3K INHIBITOR, AND CETUXIMAB IN PATIENTS WITH PIK3CAMUTATED METASTATIC COLORECTAL CANCER FAILING IRINOTECAN, OXALIPLATIN, 5-FU AND ANTI-EGFR CONTAINING REGIMENS
2019-003727-38CANCER COLORRECTAL MUTADO PIK3CAFundación Jiménez DíazInvestigador: DOGER DE SPEVILLE BERNARD
